The team also looked at COX-2 inhibitors, a new generation anti-inflammatory drug.
To evaluate the effects of both drugs, researchers analysed randomised control trials comparing NSAID, with other forms of the anti-inflammatory pill or placebo.
A total of thirty-one trials were completed, with 116,429 patients involved.
The results revealed that rofecoxib and lumiracoxib were associated with twice the risk of heart attack when compared with placebo.
Published at Mon, 10 Jan 2022 15:37:00 +0000